American Journal of Cardiology
Volume 105, Issue 8 , Pages 1076-1082 , 15 April 2010

Comparison by Meta-Analysis of Drug-Eluting Stents and Bare Metal Stents for Saphenous Vein Graft Intervention

  • Michael S. Lee, MD

      Affiliations

    • Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California
    • Corresponding Author InformationCorresponding author: Tel: (301) 696-9523; fax: 310-206-3607
    • ,
  • Tae Yang, MD

      Affiliations

    • Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California
    • ,
  • David E. Kandzari, MD

      Affiliations

    • Division of Cardiology, Scripps Clinic, La Jolla, California
    • ,
  • Jonathan M. Tobis, MD

      Affiliations

    • Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California
    • ,
  • Hsini Liao, PhD

      Affiliations

    • Boston Scientific Corporation, Natick, Massachusetts
    • ,
  • Ehtisham Mahmud, MD

      Affiliations

    • Division of Cardiology, University of California, San Diego, School of Medicine, San Diego, California

Received 2 October 2009 ,Revised 3 December 2009 ,Accepted 3 December 2009.

References 

  1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
  4. Assali A, Raz Y, Vaknin-Assa H, Ben-Dor I, Brosh D, Teplitsky I, et al. Beneficial 2-year results of drug-eluting stents in saphenous vein graft lesions. Eur Interv. 2008;4:108–114
  5. van Twisk PH, Daemen J, Kukreja N, van Domburg RT, Serruys PW. Four-year safety and efficacy of the unrestricted use of sirolimus and paclitaxel-eluting stents in coronary artery bypass grafts. Eur Interv. 2008;4:311–317
  6. Okabe T, Lindsay J, Buch AN, Steinberg DH, Roy P, Slottow TL, et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol. 2008;102:530–534
  7. Jeger RV, Schneiter S, Kaiser C, Bonetti POBrunner-La Rocca H, Handke M, Osswald S, et al. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology. 2008;112:49–55
  8. Kaplan S, Barlis P, Kiris A, Dimopoulos K, Celik S, Di Mario C. Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. Acute Card Care. 2008;10:88–92
  9. Gioia G, Benassi A, Mohendra R, Chowdhury K, Masood I, Matthai W. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv. 2008;72:13–20
  10. Ramana RK, Ronan A, Cohoon K, Homan D, Sutherland J, Steen L, et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv. 2008;71:886–893
  11. Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, Varani E, et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna Registry). Am J Cardiol. 2008;101:947–952
  12. Bansal D, Muppidi R, Singla S, Sukhija R, Zarich S, Mehta JL, et al. Percutaneous intervention on the saphenous vein bypass grafts—long-term outcomes. Catheter Cardiovasc Interv. 2008;71:58–61
  13. Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DN, Cuomo LJ, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol. 2007;20:458–465
  14. Ellis SG, Kandzari D, Kereiakes DJ, Pichard A, Huber K, Resnic F, et al. Utility of sirolimus-eluting Cypher™ stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol. 2007;19:404–409
  15. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van Den Branden F, et al. DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators (Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial). J Am Coll Cardiol. 2007;50:261–267
  16. Hoffmann R, Pohl T, Koster R, Blindt R, Boeckstegers P, Heitzer T. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart. 2007;93:331–334
  17. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv. 2005;66:507–511
  18. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45:989–994
  19. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, et al. A randomized-controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions. J Am Coll Cardiol. 2009;53:919–928
  20. Lozano I, García-Camarero T, Carrillo P, Baz JA, de La Torre JM, López-Palop R, et al. Comparison of drug-eluting and bare metal stents in saphenous vein grafts (Immediate and long-term results). Rev Esp Cardiol. 2009;62:39–47
  21. Wohrle J, Nusser T, Kestler HA, Kochs M, Hombach V. Comparison of the slow-release polymer based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol. 2007;96:70–76
  22. Guo JC, Xu M, Wang GZ, Ma CS. Late lumen loss of drug eluting stents versus bare metal stents for saphenous vein graft intervention. J Clin Rehab Tiss Eng Res. 2008;12:6971–6975
  23. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial. J Am Coll Cardiol. 2006;48:2423–2431
  24. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting vs. bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  25. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088–2092
  26. Wessely R, Kastrati A, Schömig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 2005;143:392–394
  27. Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol. 2001;38:659–665
  28. de Jaegere PP, van Domburg RT, Feyter PJ, Ruygrok PN, van der Giessen WJ, van den Brand MJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol. 1996;28:89–96

 Dr. Lee is a member of the Speaker's Bureau for Schering-Plough, Kenilworth, New Jersey, Boston Scientific Corporation, Boston, Massachusetts, and Bristol-Myers Squibb, New York, New York. Dr. Tobis is a member of the Speaker's Bureau for Boston Scientific Corporation, Boston, Massachusetts. Dr. Mahmud has received research grants for clinical trials from Boston Scientific, Boston, Massachusetts, and Abbott Vascular, and is on the Speakers List for Medtronic. Dr. Kandzari has received research grant support from Medtronic, Santa Rosa, California, and is a consultant to Cordis, Johnson & Johnson, Warren, New Jersey. Dr. Liao is an employee of Boston Scientific Corporation, Boston, Massachusetts.

PII: S0002-9149(09)02834-3

doi: 10.1016/j.amjcard.2009.12.006

American Journal of Cardiology
Volume 105, Issue 8 , Pages 1076-1082 , 15 April 2010

Article Tools

* Image Usage & Resolution